Ayala Pharmaceuticals (ADXS) Competitors $0.03 -0.01 (-25.19%) As of 05/15/2025 11:10 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. SNGX, PLRZ, KLTO, PTN, EVOK, APM, TCRT, ADIL, ONCO, and ALZNShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Soligenix (SNGX), Polyrizon (PLRZ), Klotho Neurosciences (KLTO), Palatin Technologies (PTN), Evoke Pharma (EVOK), Aptorum Group (APM), Alaunos Therapeutics (TCRT), Adial Pharmaceuticals (ADIL), Onconetix (ONCO), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Soligenix Polyrizon Klotho Neurosciences Palatin Technologies Evoke Pharma Aptorum Group Alaunos Therapeutics Adial Pharmaceuticals Onconetix Alzamend Neuro Soligenix (NASDAQ:SNGX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community prefer SNGX or ADXS? Soligenix received 278 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSoligenixOutperform Votes27872.97% Underperform Votes10327.03% Ayala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes86100.00% Does the media favor SNGX or ADXS? In the previous week, Soligenix had 5 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for Soligenix and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Soligenix's score of -0.16 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, SNGX or ADXS? Soligenix has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Which has preferable earnings & valuation, SNGX or ADXS? Soligenix has higher earnings, but lower revenue than Ayala Pharmaceuticals. Soligenix is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoligenix$840K7.38-$6.14M-$4.29-0.44Ayala Pharmaceuticals$3.24M0.39-$48.07M-$7.980.00 Do insiders & institutionals have more ownership in SNGX or ADXS? 3.6% of Soligenix shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 2.8% of Soligenix shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is SNGX or ADXS more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Soligenix's net margin of -1,473.38%. Ayala Pharmaceuticals' return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Soligenix-1,473.38% -223.29% -74.18% Ayala Pharmaceuticals N/A N/A N/A SummarySoligenix beats Ayala Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28M$6.38B$5.28B$8.46BDividend YieldN/A2.65%4.95%4.17%P/E Ratio0.008.8926.5319.69Price / Sales0.39269.76399.32120.60Price / CashN/A65.8538.3134.62Price / Book-0.016.346.684.52Net Income-$48.07M$143.46M$3.22B$248.10M7 Day PerformanceN/A4.81%4.18%4.49%1 Month PerformanceN/A10.65%10.60%13.85%1 Year PerformanceN/A-6.31%13.86%5.82% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-25.2%N/A-84.2%$1.28M$3.24M0.0020Analyst ForecastGap DownSNGXSoligenix0.2755 of 5 stars$1.95+1.1%N/A-67.8%$4.88M$840,000.00-0.2620Earnings ReportNegative NewsPLRZPolyrizonN/A$1.14+12.9%N/AN/A$4.78MN/A0.00N/AGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$0.17-2.7%N/AN/A$4.76MN/A0.00N/AEarnings ReportNews CoverageGap UpPTNPalatin TechnologiesN/A$0.18-17.5%N/AN/A$4.68M$350,000.00-0.1230Gap DownHigh Trading VolumeEVOKEvoke Pharma0.2246 of 5 stars$3.09flatN/A-43.6%$4.61M$10.25M-0.284Earnings ReportAnalyst ForecastGap DownAPMAptorum Group1.0692 of 5 stars$0.86-7.5%N/A-79.0%$4.60M$430,000.000.0030Gap DownTCRTAlaunos Therapeutics0.3401 of 5 stars$2.85+12.6%N/A-76.3%$4.56M$10,000.000.0040Earnings ReportUpcoming EarningsADILAdial Pharmaceuticals3.3716 of 5 stars$0.69+2.9%$8.00+1,060.3%-53.5%$4.53MN/A-0.2120Earnings ReportNews CoverageONCOOnconetix0.595 of 5 stars$0.07+0.6%N/A-98.3%$4.53M$1.87M0.0012ALZNAlzamend Neuro3.3819 of 5 stars$0.68+1.5%$20.00+2,841.2%-94.1%$4.49MN/A0.004News CoverageGap Up Related Companies and Tools Related Companies Soligenix Alternatives Polyrizon Alternatives Klotho Neurosciences Alternatives Palatin Technologies Alternatives Evoke Pharma Alternatives Aptorum Group Alternatives Alaunos Therapeutics Alternatives Adial Pharmaceuticals Alternatives Onconetix Alternatives Alzamend Neuro Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 5/16/2025 by MarketBeat.com Staff From Our PartnersTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored“Market Wizard” signals rare opportunityThe Fed Is Losing Control — What Comes Next Will Shock Traders The Fed is stuck — rising inflation and risi...Brownstone Research | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredCan This System Really Predict Stocks to the Day?Imagine foreseeing a 30% stock jump — to the day — weeks before it happens. Introducing a new way to predict t...InvestorPlace | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
